mhs

Express Scripts announced it was buying Medco for $29.1 billion in cash and stock.

Amerisource is Medco's primary supplier of pharmaceutical products for its mail-order business.

AmerisourceBergen has a potential upside of 14.9% based on a current price of $39.41 and an average consensus analyst price target of $45.29.

AmerisourceBergen (NYSE:ABC) fell 5% to $39.78 on worries that the company's worthwhile contract with Medco Health Solutions (NYSE:MHS) could be jeopardized now that it is being acquired by Express Scripts (NASDAQ:ESRX)

Equity futures are pointing higher this morning with the Dow Jones Industrial Average looking to open 72 points higher while the broader S&P500 index is looking to open over 8 points higher.

The company sees 2011 EPS of $4.02 to $4.12, vs. consensus estimates of $4.10 per share.

David B. Snow Jr., chairman and chief executive officer of Medco said, "Medco's second-quarter results are characterized by strong performance across the enterprise.

Medco Health Solutions (NYSE:MHS) reported Q2 EPS of $0.96, ex-items, ahead of consensus estimates of $0.94 per share. Revenues for the quarter rose 3.5% year-over-year to $16.72 billion, missing consensus estimates of $17.07 bill

An $11 billion contract with UnitedHealth Group (NYSE:UNH) expires after 2012, the report noted. UnitedHealth is currently reviewing the contract.

Medco shares are up 0.69%, or $0.38, to $57.15.

Shares of Medco Health Solutions (NYSE:MHS) are higher in after-hours trading after Bloomberg reported that the pharmacy benefits manager may be seeking acquisitions to make up for lost sales.

The analysis is being presented today at the International Conference on Viral Hepatitis 2011.

Medco Health Solutions (MHS) today announced that in a new observational analysis it has conducted, Hepatitis C patients who also being treated for depression -- a frequent side effect of the Hepatitis C drug interferon --are more

Morgan Stanley lowered its 2011 EPS estimate for Medco Health Solutions (NYSE:MHS) and maintained its overweight rating, with a $69 price target. The bank now sees 2011 EPS of $3.57, down from $3.60 per share. Shares of the compan

The company reaffirmed its outlook and sees full-year EPS of $3.99-$4.12, vs.

Medco Health (NYSE:MHS) reported Q4 EPS of 94 cents, ex-items, inline with consensus estimates. Revenue totaled $16.93 billion, better than the $16.65 billion analysts were expecting. EBITDA increased 13.2 percent to a record $786